Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
60°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rezolute Inc
(NQ:
RZLT
)
3.100
+0.290 (+10.32%)
Streaming Delayed Price
Updated: 1:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Rezolute Inc
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
May 15, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
April 23, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High
April 15, 2024
Via
Investor Brand Network
3 Stocks Insiders Are Buying That Analysts Love
March 26, 2024
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits.
Via
MarketBeat
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
March 06, 2024
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism)
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
February 13, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
January 24, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
January 23, 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
December 13, 2023
Plans to report topline data mid-second quarter 2024
From
Rezolute, Inc.
Via
GlobeNewswire
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
November 24, 2023
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday...
Via
Newsfile
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
November 17, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports First Quarter Fiscal 2024 Results
November 13, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
October 17, 2023
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
October 11, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
September 14, 2023
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences in September
September 06, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
June 27, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
June 01, 2023
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare...
Via
Newsfile
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
May 11, 2023
The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
March 23, 2023
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
March 08, 2023
Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
February 10, 2023
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
December 15, 2022
RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
November 09, 2022
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute to Present at the Jefferies London Healthcare Conference
November 01, 2022
From
Rezolute, Inc.
Via
GlobeNewswire
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
October 20, 2022
From
Rezolute, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Rezolute Inc. (NASDAQ: RZLT) Announces Underwritten Public Offering, Concurrent Registered Direct Offering
November 01, 2021
Via
Investor Brand Network
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.